England’s Cancer Drugs Fund to Provide Keytruda for Cervical Cancer

After a recommendation from the UK’s National Institute for Health and Care Excellence (NICE), England’s Cancer Drugs Fund (CDF) announced it will cover Merck’s (MSD in the UK) Keytruda for patients living with advanced metastatic cervical cancer. This opens up a new avenue of treatment for the thousands of women diagnosed with the disease in England each year.

According to Emily Kimber, “The company’s application was supported by results from a phase 3 study in which the addition of Keytruda to chemotherapy was associated with a significant improvement in progression-free survival and overall survival in this patient population.”

To read more, click here.

(Source: PM Live, March 29^th, 2023)